Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Elu...( SPIRIT III Results Demonstrate Super...),Health

SPIRIT III Results Demonstrate Superior Reduction in In-Segment Late Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE with XIENCE

V Compared to TAXUS

ABBOTT PARK, Ill., April 22 /PRNewswire-FirstCall/ -- A study published in today's Journal of the American Medical Association (JAMA) demonstrated that use of Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System in patients with coronary artery disease resulted in a significant 50 percent reduction in vessel renarrowing (in-segment late loss) at eight months, non-inferior rates of target vessel failure (TVF) at nine months, and an observed 42 percent reduction in major adverse cardiac events (MACE) at one year compared to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System. The SPIRIT III study is a 1,002-patient, prospective, multi-center, randomized clinical trial designed to evaluate the safety and efficacy of the XIENCE V stent system compared to the TAXUS stent system.

"SPIRIT III is the first large-scale clinical trial to show that patients have a lower risk of experiencing a heart attack, cardiac death or re-treatment when treated with a new stent, XIENCE V, compared to the most widely used drug eluting stent TAXUS," said Gregg W. Stone, M.D., of the Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III clinical trial. "With a significant reduction in angiographic in-segment late loss, non-inferiority in target vessel failure and a clinical advantage in the composite rate of MACE compared to TAXUS, XIENCE V represents an important advance in improving the lives of patients with coronary artery disease."

The SPIRIT III clinical trial demonstrated the following key results for XIENCE V:
-- Statistical superiority to TAXUS on the study's primary endpoint of

in-segment late loss at eight months. XIENCE V demonstrated a

'/>"/>